Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen.
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Pfizer Inc
Deal Size : $5,400.0 million
Deal Type : Acquisition
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Details : Proposed acquisition drives growth by bringing leading sickle cell disease expertise and rare hematology portfolio and pipeline of GBT including Oxbryta (voxelotor) tablets for treatment of sickle cell disease (SCD) and GBT601.
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : $5,400.0 million
August 08, 2022
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Pfizer Inc
Deal Size : $5,400.0 million
Deal Type : Acquisition
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
Details : Oxbryta (Voxelotor) works by increasing hemoglobin’s affinity for oxygen, inhibits sickle hemoglobin polymerization and resultant sickling and destruction of red blood cells leading to hemolysis and anemia, are primary pathologies faced by every single...
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Pfizer Inc
Deal Size : $5,400.0 million
Deal Type : Acquisition
Pfizer Completes Acquisition of Global Blood Therapeutics
Details : Acquisition brings leading sickle cell disease portfolio and pipeline including Oxbryta® (voxelotor), a first-in-class medicine that directly targets the root cause of SCD, to Pfizer with potential to address critical needs in an underserved patient com...
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : $5,400.0 million
May 10, 2022
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Pfizer Inc
Deal Size : $5,400.0 million
Deal Type : Acquisition
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term complications of sickle cell disease.
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2022
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This positive opinion means that those patients living with SCD and meeting the eligibility criteria can gain early, pre-license access to voxelotor, while the MHRA completes its review of the Marketing Authorisation Application (MAA).
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHMP opinion is based on Phase 3 HOPE study which demonstrated clinically meaningful and statistically significant improvements in Hb levels and reductions in hemolysis, for patients treated with Oxbryta (Voxelotor) as monotherapy or in combination with ...
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2021
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The FDA’s approval of the sNDA is based on data from the open-label Phase 2a HOPE-KIDS 1 Study, which showed that weight-based treatment with the dispersible tablet formulation of Oxbryta (Voxelotor) resulted in rapid and sustained improvements in hemo...
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2021
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $300.0 million
Deal Type : Public Offering
GBT Announces Pricing of Upsized Offering of $300.0 Million of Convertible Senior Notes
Details : GBT intends to use the remainder of the net proceeds from the offering for the continued commercialization of Oxbryta® (voxelotor) and the clinical development of Oxbryta® and GBT’s product candidates.
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2021
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $300.0 million
Deal Type : Public Offering
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A new analysis of data from 45 children with SCD ages 4 to 11 years enrolled in the open-label Phase 2a HOPE-KIDS 1 Study (GBT440-007) showed that treatment with Oxbryta resulted in rapid and sustained improvements in hemoglobin
Product Name : Oxbryta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2021
Lead Product(s) : Voxelotor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable